SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer.
A. Tsuburaya
No relevant relationships to disclose
K. Yoshida
No relevant relationships to disclose
M. Kobayashi
No relevant relationships to disclose
S. Yoshino
No relevant relationships to disclose
Y. Miyashita
No relevant relationships to disclose
S. Morita
No relevant relationships to disclose
K. Oba
No relevant relationships to disclose
M. E. Buyse
No relevant relationships to disclose
J. S. Macdonald
No relevant relationships to disclose
J. Sakamoto
No relevant relationships to disclose